❦ ‘COVID-19 patients have a hypercoagulability state, and thrombosis is a life-threatening complication of them.’

✻ Hypercoagulability, also known as thrombophilia, is a condition in which there is an abnormally increased tendency towards blood clotting.

‘From the early days of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak to the present, clinical and basic studies have indicated that coronavirus disease 2019 (COVID-19) may be associated with coagulopathy (CAC), which is involved in its related morbidity and mortality.

Deep vein thrombosis (DVT) and pulmonary embolism (PE) are common in COVID-19 patients and are remarkably high in the intensive care unit (ICU)–admitted patients.

CAC can lead to the formation of circulating microthrombi and macrothrombi which can involve multiple sites, including the lungs, brain, heart, and visceral organs like kidneys and spleen.

There is a close relationship between the immune system and coagulation.

The components of the hemostatic system play a role in the body’s immunity, and the activation of the immune system strongly influences the hemostatic system.

Abnormal activation of the immune system may promote the growth of pathologies associated with thrombosis.

COVID-19 is accompanied by an immune-cell hyperactivation and excessive production of proinflammatory cytokines, known as “cytokine storm”.

CAC is theorized to result from dysregulated interactions between the immune and coagulation systems.’

❂

📖 (19 Apr 2023 ~ Annals of Hematology) Status of major hemostatic components in the setting of COVID-19: the effect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement ➤

© 2023 Annals of Hematology.